{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-211808","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.775423+00:00","generated_at":"2026-06-24T03:55:21.551371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Agios Q2 2022: PYRUKYND revenue $3.1M; net loss $91.8M; CEO transition to Brian Goff","bullets":["Q2 2022 net loss from continuing ops $91.8M vs $82.8M Q2 2021; R&D expenses rose to $74.5M.","PYRUKYND generated $3.1M net U.S. revenue in first full quarter after Feb 2022 FDA approval.","Cash, equivalents, marketable securities $1.1B, down from $1.7B; expects to fund to cash-flow positivity.","Brian Goff becomes CEO Aug 8; current CEO Jackie Fouse transitions to Chair of Board.","Five pivotal PYRUKYND studies enrolling across thalassemia, sickle cell, pediatric PK deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-211808","json":"https://secwatch.observer/filing/0001193125-22-211808.json","markdown":"https://secwatch.observer/filing/0001193125-22-211808.md","text":"https://secwatch.observer/filing/0001193125-22-211808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/0001193125-22-211808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/d389470d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:55:21.551371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}